Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 244Observational 44Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 9Small Cell Lung Carcinoma 8Pancreatic Neoplasms 7Prostatic Neoplasms 5Ovarian Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma 3Thyroid Neoplasms 2Neoplasms 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Sarcoma, Synovial 1Rhabdoid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1

Interventions

Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Mesothelioma × Thoracic × Clear all
NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Eli Lilly and Company

Approved for marketing
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡